ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies

AC Raulin, SV Doss, ZA Trottier, TC Ikezu, G Bu… - Molecular …, 2022 - Springer
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

The amyloid-β pathway in Alzheimer's disease

H Hampel, J Hardy, K Blennow, C Chen, G Perry… - Molecular …, 2021 - nature.com
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

[HTML][HTML] Cholesterol and matrisome pathways dysregulated in astrocytes and microglia

TCW Julia, L Qian, NH Pipalia, MJ Chao, SA Liang… - Cell, 2022 - cell.com
The impact of apolipoprotein E ε4 (APOE4), the strongest genetic risk factor for Alzheimer's
disease (AD), on human brain cellular function remains unclear. Here, we investigated the …

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

GB Frisoni, D Altomare, DR Thal, F Ribaldi… - Nature Reviews …, 2022 - nature.com
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases

R Fernández-Calle, SC Konings… - Molecular …, 2022 - Springer
ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

[HTML][HTML] Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases

U Sengupta, R Kayed - Progress in neurobiology, 2022 - Elsevier
Aggregation of specific proteins are histopathological hallmarks of several
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …

[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review

D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies

Y Yamazaki, N Zhao, TR Caulfield, CC Liu… - Nature Reviews …, 2019 - nature.com
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …

[HTML][HTML] Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity

MB Victor, N Leary, X Luna, HS Meharena… - Cell Stem Cell, 2022 - cell.com
Summary Apolipoprotein E4 (APOE4) is the greatest known genetic risk factor for
developing sporadic Alzheimer's disease. How the interaction of APOE4 microglia with …

Apolipoprotein E and Alzheimer's disease: findings, hypotheses, and potential mechanisms

N Koutsodendris, MR Nelson, A Rao… - Annual Review of …, 2022 - annualreviews.org
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that involves
dysregulation of many cellular and molecular processes. It is notoriously difficult to develop …